EMA
approval
· 2025-04-11
EMA Authorised: Cinqaero (reslizumab) — Teva B.V.
Summary
The European Medicines Agency authorised Cinqaero (reslizumab) by Teva B.V. for the treatment of asthma in the European Union.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Status: Authorised. Therapeutic area: Asthma. MAH: Teva B.V.. Decision date: 11/04/2025